Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03668119
Recruitment Status : Recruiting
First Posted : September 12, 2018
Last Update Posted : January 10, 2020
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 15, 2021
Estimated Study Completion Date : October 31, 2023